ARN25699
ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C21H21N7O2
- Masse moléculaire:403.44
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
GSK-3β |
DYRK1A |
Fyn-α |
ARN25699 (Compound 28) (0.1-10 μM) inhibits a subset of kinases associated with the pathogenesis of Alzheimer's disease[1].
ARN25699 (1-100 μM; 6 h) induces dose-dependent microtubule bundle formation in Tau0N4R-TM-tGFP U2OS cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Masse moléculaire 403.44
-
Formule C21H21N7O2
-
SMILES
O=C(N)C1=CC=CC(CNC2=NC(NC3=NNC(C4CCC4)=C3)=C(OC=C5)C5=N2)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ARN25699 Related Classifications
HY-183584 Related Classifications
Powered by Bioz